Giving to Canary Foundation supports programs that redefine cancer early detection.
Help us set the pace for innovation by donating today.
Finding cancer earlier, more accurately and cost effectively.
It’s about time.
For over 10 years, Canary has been the only foundation in the world focused solely on early cancer detection. Learn More »
Giving to Canary Foundation supports programs that redefine cancer early detection.
Help us set the pace for innovation by donating today.
See Canary’s progress in early cancer detection solutions.
2000
Don Listwin’s mother, Grace Listwin, misdiagnosed with bladder infection |
2001
Grace Listwin dies of late-stage ovarian cancer due to detection of her cancer at a late stage |
2002
Ovarian cancer biomarker work for Dr. Nicole Urban funded by Listwin Family Foundation at the Fred Hutch Cancer Research Center (FHCRC) in Seattle |
2003
Center of Excellence for early cancer detection established by Dr. Lee Hartwell at FHCRC focusing on cancer biomarkers First Canary science team formed—ovarian cancer |
2004
Canary Foundation formed by Don Listwin |
2005
Second Canary science team formed—pancreatic cancer First annual Scientific Symposium |
2006
Discovery of gene mutation in pancreatic cancer Partnership with Canadian British Columbia Cancer Agency to build antibodies and assays for blood biomarkers |
2007
Two more Canary science teams formed—prostate and lung |
2008
Prostate Active Surveillance Study (PASS) enrolls first patients Canary ovarian team conducts preclinical validation of ovarian biomarker HE4 |
2009
Founded Canary Center at Stanford with Stanford School of Medicine and Stanford Cancer Institute Canary ovarian team launches Novel Markers Trial Magneto-nano sensor developed to detect biomarkers—10,000 times more sensitive than existing tests |
2009Continued
Never Smokers Lung Cancer Study launches Don Listwin named to National Cancer Institute Board of Scientific Advisors |
2010
Lung cancer imaging trial begins at Stanford Stanford team builds photoacoustic device for prostate cancer (begins testing in 2011) Parag Mallick & Sharon Pitteri hired—first full-time faculty at Stanford dedicated 100% to early cancer detection |
2011
Gene fusion discovered for ovarian cancer Canary pancreatic cancer team demonstrates microbubble imaging to below 1 mm in size Canary lung cancer team discovers novel biomarker that defines patients as high-risk |
2012
Breast Cancer Program launched Stanford Cancer Institute Awards Canary Foundation with Spirit of Hope Award |
2013
Stanford moves Canary Center to Stanford’s Technology and Innovation Park—2x lab space Genomic Health partners with PASS team to work on detection test for prostate cancer Microbubble clinical trials in ovarian and breast cancer begin in Rome |
2014
FDA approves ultrasound using microbubble—trials begin for men with prostate cancer at Stanford Canary prostate cancer team—PASS wins competitive NCI award Partnership with MD Anderson to build national lung cancer screening trial |
2014Continued
Clinical trials begin in partnership with El Camino Hospital for pancreatic early cancer detection Canary Center recruits Utkan Demirci from Harvard/MIT with expertise in biomedical microfluidic technology platforms
|
2014Continued
CRUK launches early cancer detection initiatives in UK OHSU launches billion-dollar early detection initiative |
2015
Tom Soh recruited from UCSB—focusing on portable, rapid, and sensitive diagnostic platforms Canary develops Canary Quantum Cloud to give researchers access to new machine-learning platform |
Five-Year Goals
Ovarian cancer biomarkers go to all national high-risk clinics Microbubble technology approved for breast cancer Microbubble approved for pancreatic cancer |
Five-Year GoalsContinued
Photoacoustics imaging trials in prostate and ovarian cancers concluded and move to national high-risk clinics Prostate prognostic test available commercially International lung cancer biomarker trial ongoing |
2000
Don Listwin’s mother, Grace Listwin, misdiagnosed with bladder infection |
2001
Grace Listwin dies of late-stage ovarian cancer due to detection of her cancer at a late stage |
2002
Ovarian cancer biomarker work for Dr. Nicole Urban funded by Listwin Family Foundation at the Fred Hutch Cancer Research Center (FHCRC) in Seattle |
2003
Center of Excellence for early cancer detection established by Dr. Lee Hartwell at FHCRC focusing on cancer biomarkers First Canary science team formed—ovarian cancer |
2004
Canary Foundation formed by Don Listwin |
2005
Second Canary science team formed—pancreatic cancer First annual Scientific Symposium |
2006
Discovery of gene mutation in pancreatic cancer Partnership with Canadian British Columbia Cancer Agency to build antibodies and assays for blood biomarkers |
2007
Two more Canary science teams formed—prostate and lung |
2008
Prostate Active Surveillance Study (PASS) enrolls first patients Canary ovarian team conducts preclinical validation of ovarian biomarker HE4 |
2009
Founded Canary Center at Stanford with Stanford School of Medicine and Stanford Cancer Institute Canary ovarian team launches Novel Markers Trial Magneto-nano sensor developed to detect biomarkers—10,000 times more sensitive than existing tests |
2009 Continued
Never Smokers Lung Cancer Study launches Don Listwin named to National Cancer Institute Board of Scientific Advisors |
2010
Lung cancer imaging trial begins at Stanford Stanford team builds photoacoustic device for prostate cancer (begins testing in 2011) Parag Mallick & Sharon Pitteri hired—first full-time faculty at Stanford dedicated 100% to early cancer detection |
2011
Gene fusion discovered for ovarian cancer Canary pancreatic cancer team demonstrates microbubble imaging to below 1 mm in size Canary lung cancer team discovers novel biomarker that defines patients as high-risk |
2012
Breast Cancer Program launched Stanford Cancer Institute Awards Canary Foundation with Spirit of Hope Award |
2013
Stanford moves Canary Center to Stanford’s Technology and Innovation Park—2x lab space Genomic Health partners with PASS team to work on detection test for prostate cancer Microbubble clinical trials in ovarian and breast cancer begin in Rome |
2014
FDA approves ultrasound using microbubble—trials begin for men with prostate cancer at Stanford Canary prostate cancer team—PASS wins competitive NCI award Partnership with MD Anderson to build national lung cancer screening trial |
2014 Continued
Clinical trials begin in partnership with El Camino Hospital for pancreatic early cancer detection Canary Center recruits Utkan Demirci from Harvard/MIT with expertise in biomedical microfluidic technology platforms
|
2014 Continued
CRUK launches early cancer detection initiatives in UK OHSU launches billion-dollar early detection initiative |
2015
Tom Soh recruited from UCSB—focusing on portable, rapid, and sensitive diagnostic platforms Canary develops Canary Quantum Cloud to give researchers access to new machine-learning platform |
Five-Year Goals
Ovarian cancer biomarkers go to all national high-risk clinics Microbubble technology approved for breast cancer Microbubble approved for pancreatic cancer |
Five-Year Goals Continued
Photoacoustics imaging trials in prostate and ovarian cancers concluded and move to national high-risk clinics Prostate prognostic test available commercially International lung cancer biomarker trial ongoing |
Our goal is to raise more than $1 million for cancer early detection research. With 5 routes—starting with a family friendly 5K run/walk/ride and going all the way up to the 100-mile Canary Century, this day-long festival has something for everyone.
Learn More »Attendees of this semi-annual event come together to celebrate Canary’s successes in cancer early detection, discuss the latest technology and research developments, and review advances on the horizon.
Learn More »